Intrinsic Imaging Awarded Large Pivotal Phase III Oncology Trial for Metastatic Breast Cancer

Bolton, MA / San Antonio, TX — July 13, 2016 — Intrinsic Imaging, an FDA audited, ISO 9001, 13485 and 22301 certified imaging core lab, announced today that it has been awarded a global Phase III clinical trial designed to investigate the safety, tolerability and efficacy of a new oral chemotherapeutic for the treatment of metastatic breast cancer.

With its team of seventy full-time, board-certified, fellowship trained radiologists, Intrinsic Imaging has extensive experience in providing services in support of Phase I-IV Clinical Trials and Class I, II and III Medical Device Trials across all therapeutic areas and indications.

Intrinsic Imaging’s Oncology Team consists of 10 full-time radiologists with a breadth of experience in clinical trials involving carcinomas, sarcomas, myeloma, leukemia and lymphoma. The team also has significant expertise in a range of assessment criteria including, but not limited to, RECIST, PERCIST, Cheson, irRECIST, RANO and Macdonald.

Throughout this Phase III trial, which includes thousands of radiological reviews, Intrinsic Imaging will provide comprehensive imaging core lab services including protocol and charter development, site qualification, site training and management, image transfer, radiological review and data management.

“Intrinsic Imaging has significant experience and expertise in the assessment of cancer,” said Todd A. Joron, BSc., MBA, President & COO at Intrinsic Imaging. “Our operational expertise, our experienced radiologists and our ISO certified quality management system allows us to be a valued partner with this Sponsor in their effort to treat metastatic breast cancer.”

Breast cancer is the second leading cause of cancer deaths in women in the United States. According to American Cancer Society, an estimated 246,000 new cases of invasive breast cancer are expected to be diagnosed in the US in 2016.